GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arix Bioscience PLC (LSE:ARIX) » Definitions » Debt-to-EBITDA

Arix Bioscience (LSE:ARIX) Debt-to-EBITDA : -0.01 (As of Jun. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Arix Bioscience Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Arix Bioscience's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was £0.04 Mil. Arix Bioscience's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was £0.00 Mil. Arix Bioscience's annualized EBITDA for the quarter that ended in Jun. 2023 was £-5.79 Mil. Arix Bioscience's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 was -0.01.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Arix Bioscience's Debt-to-EBITDA or its related term are showing as below:

LSE:ARIX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.08   Med: -0.03   Max: -0.01
Current: -0.01

During the past 7 years, the highest Debt-to-EBITDA Ratio of Arix Bioscience was -0.01. The lowest was -0.08. And the median was -0.03.

LSE:ARIX's Debt-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 1.36 vs LSE:ARIX: -0.01

Arix Bioscience Debt-to-EBITDA Historical Data

The historical data trend for Arix Bioscience's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arix Bioscience Debt-to-EBITDA Chart

Arix Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Get a 7-Day Free Trial - -0.08 -0.04 -0.03 -0.01

Arix Bioscience Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.03 -0.02 -0.01 -0.01

Competitive Comparison of Arix Bioscience's Debt-to-EBITDA

For the Biotechnology subindustry, Arix Bioscience's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arix Bioscience's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arix Bioscience's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Arix Bioscience's Debt-to-EBITDA falls into.



Arix Bioscience Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Arix Bioscience's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.059 + 0.011) / -5.064
=-0.01

Arix Bioscience's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.037 + 0) / -5.792
=-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2023) EBITDA data.


Arix Bioscience  (LSE:ARIX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Arix Bioscience Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Arix Bioscience's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Arix Bioscience (LSE:ARIX) Business Description

Traded in Other Exchanges
N/A
Address
50 Duke Street, Duke Street House, London, GBR, W1K 6JL
Arix Bioscience PLC is a healthcare and life science company. Its business model is to source, finance, and develop healthcare and life science businesses that deliver or seek to deliver therapies to patients. Its segment includes sourcing, financing, and developing healthcare and life science businesses globally.

Arix Bioscience (LSE:ARIX) Headlines

No Headlines